Comparative Pharmacology
Head-to-head clinical analysis: CO LAV versus ENULOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CO LAV versus ENULOSE.
CO-LAV vs ENULOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic pH and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
15-45 mL orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 mL per day.
None Documented
None Documented
Unknown
Terminal elimination half-life is 2.1 hours in normal renal function; prolonged to up to 6 hours in renal impairment.
CO-LAV is not a recognized drug. Please check the drug name.
Primarily renal (95% unchanged by glomerular filtration); biliary/fecal less than 5%.
Category C
Category C
Laxative/Bowel Evacuant
Laxative